Akeso’s ivonescimab posts 14.9-month median OS vs. 12.1 for Imfinzi in China Ph3 biliary tract cancer trial at ESMO.

MADRID — As­traZeneca said Sun­day it might have found a way for pa­tients with mu­tant non-small cell lung can­cer to keep ...

Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis.

Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.

Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...

The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell ...

As with many of the most feared neu­ro­log­i­cal con­di­tions, Hunt­ing­ton’s dis­ease has proven to be a mine­field for drug de­vel­op­ers. Promis­ing bio­mark­er da­ta didn’t trans­late in­to ...

Biopharma M&A, licensing upfronts and VC all cooled in Q3, DealForma data show, while China’s share of pharma in-licensing kept climbing.

Al Sandrock is calling it quits as CEO of Voyager Therapeutics in the first quarter next year, but he will stay on the board.

Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...